Could a common cholesterol pill be the key to slowing a deadly kidney disease?
NCT ID NCT07282821
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This study tests whether bempedoic acid, a drug already approved for high cholesterol, can safely slow the progression of autosomal dominant polycystic kidney disease (ADPKD). About 120 adults with rapidly progressing ADPKD will receive either the drug or a placebo for two years. The main goals are to check safety and tolerability, with early signs of effectiveness also measured.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADPKD (AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tufts University Medical Center
Boston, Massachusetts, 02111, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Maryland, Baltimore
Baltimore, Maryland, 21201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
University of Vermont Medical Center
Burlington, Vermont, 05401, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.